ONC — Oncimmune Holdings Share Price
Last trade - 00:00- £1.27m
- £5.55m
- £2.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -144.66% | ||
| Return on Equity | n/a | ||
| Operating Margin | -117.78% | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.51 | 3.72 | 2.32 | 1.15 | 2.74 | 6.9 | n/a | 74.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.
Directors
- Meinhard Schmidt NEC
- Adam Hill CEO
- Matthew Hall CFO
- Ron Kirschner GCN
- Annalisa Jenkins NED (55)
- Timothy Bunting NED (58)
- Andrew Unitt NID (64)
- Last Annual
- August 31st, 2024
- Last Interim
- August 31st, 2024
- Incorporated
- October 9th, 2015
- Public Since
- May 18th, 2016
- No. of Employees
- 36
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 111,773,219
- Address
- 1 Park Row, LEEDS, LS1 5AB
- Web
- https://www.oncimmune.com/
- Phone
- +44 1158231869
- Auditors
- Gravita II LLP
Latest News for ONC
Upcoming Events for ONC
Half Year 2025 Oncimmune Holdings PLC Earnings Release
Similar to ONC
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 22:27 UTC, shares in Oncimmune Holdings are trading at 1.14p. This share price information is delayed by 15 minutes.
Shares in Oncimmune Holdings last closed at 1.14p and the price had moved by -93.39% over the past 365 days. In terms of relative price strength the Oncimmune Holdings share price has underperformed the FTSE All Share Index by -93.57% over the past year.
The overall consensus recommendation for Oncimmune Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOncimmune Holdings does not currently pay a dividend.
Oncimmune Holdings does not currently pay a dividend.
Oncimmune Holdings does not currently pay a dividend.
To buy shares in Oncimmune Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.14p, shares in Oncimmune Holdings had a market capitalisation of £1.27m.
Here are the trading details for Oncimmune Holdings:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ONC
Based on an overall assessment of its quality, value and momentum Oncimmune Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oncimmune Holdings is 50.00p. That is 4285.96% above the last closing price of 1.14p.
Analysts covering Oncimmune Holdings currently have a consensus Earnings Per Share (EPS) forecast of £0.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncimmune Holdings. Over the past six months, its share price has underperformed the FTSE All Share Index by -94.62%.
As of the last closing price of 1.14p, shares in Oncimmune Holdings were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oncimmune Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.14p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oncimmune Holdings' management team is headed by:
- Meinhard Schmidt - NEC
- Adam Hill - CEO
- Matthew Hall - CFO
- Ron Kirschner - GCN
- Annalisa Jenkins - NED
- Timothy Bunting - NED
- Andrew Unitt - NID